Parthenogenic oocyte activation
US6077710A · kind A · utility
42Cited by
4References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 1998 |
| Grant date | Jun 20, 2000 |
| Priority date | — |
| Expiry date | Oct 21, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/999
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A process of parthenogenic activation of mammalian oocytes which includes increasing intracellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca.sup.2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.